Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

TNFRSF6B (tumor necrosis factor receptor superfamily, member 6b, decoy)

Written2007-12Jiangping Wu, Bing Han
CHUM Research Center, University of Montreal, Canada

(Note : for Links provided by Atlas : click)


Alias (NCBI)DCR3 (decoy receptor 3)
TR6 (TNF receptor family member 6)
HGNC Alias symbDcR3
HGNC Previous nametumor necrosis factor receptor superfamily, member 6b, decoy
LocusID (NCBI) 8771
Atlas_Id 42628
Location 20q13.33  [Link to chromosome band 20q13]
Location_base_pair Starts at 63696652 and ends at 63698682 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping TNFRSF6B.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)


Description DNA sequence is located on chromosome 20. Transcription consists of 7 exons and 6 introns, spanning 3.6kb.
A shorter transcription variance (M68E) has been identified, and is transcribed from 3 exons and 2 introns spanning 1.9kb as illustrated above. The difference occurs at the 5' untranslated region, but the two transcripts encode the same isoform. Mice do not have a gene orthologue to human TNFRSF6B.
TNFRSF68B mRNA in Northen blot presents as a 1.2-knt band.


  A) Domains and Motifs. B) TNFRSF6B X-ray crystography
Description TNFRSF6B protein is 300-amino acid long, and has a molecular weight of 35 kD. Although TNFRSF6B belongs to the TNFR superfamily, it lacks the transmembrane and cytosolic domains in its sequence, and is a secreted protein. It contains 4 TNFR cystein-rich regions, as illustrated above.
TNFRSF6B can be easily cleaved between Arg218 and Ala219 in biological fluids and solutions. It has thus a very short (about 20 min) half-life in serum and in vivo. Mutation of arginine residue at position 218 to glutamine makes TNFRSF6B resistant to proteolysis, and significantly prolongs its half-life.
TNFRSF6B can bind to the TNF family members FasL, LIGHT and TL1A. It does not bind to other known TNF family members. Human TNFRSF6B can bind to mouse FasL, LIGHT and TL1A. This allows human DcR3/TNFRSF6B to function in mouse models both in vitro and in vivo.
The role of TNFRSF6B in apoptosis is obvious. FasL is a well-known molecule involved in apoptosis. LIGHT is a ligand for HVEM and LTbetaR, in addition to being a ligand for TNFRSF6B. LIGHT can induce apoptosis in cells expressing both HVEM and LTbetaR, or LTbetaR alone. TL1A, a member of the TNF family, can evoke apoptosis via its receptor, DR3. Consequently, the interaction of TNFRSF6B with FasL, LIGHT, and TL1A blocks apoptosis mediated by Fas, HVEM, LTbetaR and DR3.
Expression Normal tissue and cells express low-level TNFRSF6B, and healthy individuals have near-background serum TNFRSF6B levels. About 60% of malignant tumors of various tissue origins overexpress TNFRSF6B, and these patients have elevated serum TNFRSF6B levels. Serum TNFRSF6B levels of tumor patients are positively correlated to the degree of tumor malignancy and status of metastasis. It is hypothesized that malignant tumor cells secrete TNFRSF6B as a way to achieve survival advantage by blocking multiple apoptosis pathways.
Hepatocytes in liver cirrhosis have augmented TNFRSF6B expression and patients with liver cirrhosis have increased serum TNFRSF6B levels.
TNFRSF6B expression is low in resting T cells but is augmented in activated T cells, which probably represents a fine-tuning mechanism to balance the need for clonal expansion and subsequent massive activation-induced T cell death. About 40% of systemic lupus erythematosus patients have elevated serum TNFRSF6B levels.
TNFRSF6B expression in rheumatoid arthritis fibroblast-like synoviocytes is increased by TNFalpha
Localisation TNFRSF6B is a secreted protein, and is thus detected in body fluids. However, it can also be detected in cytoplasm before it is secreted.
Function As TNFRSF6B can block ligands from interacting with Fas, HVEM, LTbetaR, and DR3, all of which mediate apoptosis, it is thus can effectively inhibit apoptosis in many cell types. It is believed that many types of malignant tumors gain survival advantage by secreting TNFRSF6B which blocks tumor cell apoptosis.
Syngeneic islets transplanted to diabetes recipients survive better in the presence of administered exogenous human TNFRSF6B, due to the blockage of FasL-, LIGHT- and TL1A-triggered islets apoptosis. Transgenic expression of human TNFRSF6B in NOD mouse islets reduces diabetes pathogenesis, again, due to anti-apoptotic effect of TNFRSF6B.
The forward signaling from FasL to Fas, and from LIGHT to HVEM can provide costimulation signals to resting T cells. Blocking of these two signaling pathways reduces T cell responses to antigens. As LIGHT and FasL, although being ligands, are also transmembrane proteins, and are capable of reversely transducing costimulating signals into T cells, TNFRSF6B can also block such reverse signaling. The end result is that TNFRSF6B can reduce several costimulation pathways in T cells and inhibit T cell immune responses, such as cytokine secretion and proliferation in vitro, and cardiac allograft rejection in vivo in mouse models.
When human TNFRSF6B is linked to a transmembrane domain and is expressed on the mouse tumor cell surface, it can effectively trigger T cell costimulation via LIGHT and FasL reverse signaling, and cause effective tumor vaccination in mouse models.
When human TNFRSF6B is transgenically expressed in mice, it causes a systemic lupus erythrematosus-like syndrome. The expression of TNFRSF6B in bone marrow-derived cells is sufficient to induce this phenotype.
Recombinant human TNFRSF6B ameliorates an autoimmune crescentic glomerulonephritis model in mice.
TNFRSF6B can influence dendritic cells which in turn drive T cells to differentiate into Th2 cells.
TNFRSF6B can inhibit actin polymerization of T cells upon mitogen stimulation, and repress T-cell pseudopodium formation, which is known to be important for cell-cell interaction. As a consequence, T-cell aggregation after activation is suppressed by either soluble or solid phase TNFRSF6B.
Human T cells pretreated with soluble or solid-phase TNFRSF6B are compromised in migration in vitro and in vivo toward CXCL12. Mechanistically, a small GTPase Cdc42 fails to be activated after TNFRSF6B pretreatment of human T cells, and further downstream, p38 mitogen-activated protein kinase activation, actin polymerization, and pseudopodium formation are all down-regulated in the treated T cells.
Phagocytic activity toward immune complexes and apoptotic bodies as well as the production of free radicals and proinflammatory cytokines in response to lipopolysaccharide are impaired in TNFRSF6B-treated macrophages.


Note Not reported yet.

Implicated in

Entity Malignant tumors
Disease Oncogenesis
TNFRSF6B is overexpressed in about 60% of various malignant tumors. Its anti-apoptotic effect provides the tumors a survival advantage, and its role in reducing T cell costimulation favors tumor evasion from the immune surveillance. No TNFRSF6B gene amplification in tumors has been identified.
Diagnosis and prognosis
TNFRSF6B in sera or tumor can be used as a parameter for tumor diagnosis and prognosis. The degree of tumor malignancy is correlated to TNFRSF6B levels. When a TNFRSF6B-expressing tumor is resected, serum TNFRSF6B levels will decrease to near-zero level. The re-arising of serum TNFRSF6B in such patients will indicate tumor reoccurrence.
When TNFRSF6B is anchored on tumor cell surface, it can increase the antigenicity of the tumor, and such TNFRSF6B-expressing tumors can be used as tumor vaccine.
Entity Systemic lupus erythematosus (SLE)
Disease Pathogenesis
About 50% of SLE patients have elevated serum TNFRSF6B levels, and the levels augment during SLE flare-up. In animal models, human TNFRSF6B overexpression in mouse cells of hematopoietic origin leads to a SLE-like syndrome, suggesting a pathogenic role of TNFRSF6B in SLE.
Serum TNFRSF6B can be used as a diagnostic parameter for SLE and SLE disease activity.
Due to the pathogenic effect of TNFRSF6B on SLE, it is speculated that neutralizing TNFRSF6B might have therapeutic effect on a subpopulation of SLE patients, who are serum TNFSF6B positive.
Entity Islet primary nonfunction during islet transplantation
Disease Therapeutics
Due to the anti-apoptotic effect of TNFRSF6B, it can effectively protect islets from apoptosis during their isolation, transportation, and primary non-function after transplantation.


Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.
Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y
Acta neuropathologica. 2005 ; 109 (3) : 294-298.
PMID 15627206
Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.
Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT
Proceedings of the National Academy of Sciences of the United States of America. 2000 ; 97 (3) : 1230-1235.
PMID 10655513
Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin.
Bridgham JT, Johnson AL
Biochemical and biophysical research communications. 2003 ; 307 (4) : 956-961.
PMID 12878204
The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion.
Chang YC, Chan YH, Jackson DG, Hsieh SL
Journal of immunology (Baltimore, Md. : 1950). 2006 ; 176 (1) : 173-180.
PMID 16365408
Modulation of macrophage differentiation and activation by decoy receptor 3.
Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, Lin CH, Hsieh SL
Journal of leukocyte biology. 2004 ; 75 (3) : 486-494.
PMID 14657214
Quantification and detection of DcR3, a decoy receptor in TNFR family.
Chen J, Zhang L, Kim S
Journal of immunological methods. 2004 ; 285 (1) : 63-70.
PMID 14871535
Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells.
Fayad R, Brand MI, Stone D, Keshavarzian A, Qiao L
European journal of immunology. 2006 ; 36 (8) : 2215-2222.
PMID 16856205
Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis.
Gill RM, Hunt JS
The American journal of pathology. 2004 ; 165 (1) : 309-317.
PMID 15215185
Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome.
Han B, Moore PA, Wu J, Luo H
Arthritis and rheumatism. 2007 ; 56 (11) : 3748-3758.
PMID 17968950
Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y, Hashiramoto A, Kurosaka M, Shiozawa S, Doita M
Arthritis and rheumatism. 2007 ; 56 (4) : 1067-1075.
PMID 17393415
Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter.
Ho CH, Hsu CF, Fong PF, Tai SK, Hsieh SL, Chen CJ
Journal of virology. 2007 ; 81 (9) : 4837-4847.
PMID 17301127
Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3.
Hsu MJ, Lin WW, Tsao WC, Chang YC, Hsu TL, Chiu AW, Chio CC, Hsieh SL
Experimental cell research. 2004 ; 292 (2) : 241-251.
PMID 14697332
Modulation of dendritic cell differentiation and maturation by decoy receptor 3.
Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, Hsieh SL
Journal of immunology (Baltimore, Md. : 1950). 2002 ; 168 (10) : 4846-4853.
PMID 11994433
Attenuation of Th1 response in decoy receptor 3 transgenic mice.
Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL
Journal of immunology (Baltimore, Md. : 1950). 2005 ; 175 (8) : 5135-5145.
PMID 16210617
Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery.
Hwang SL, Lin CL, Cheng CY, Lin FA, Lieu AS, Howng SL, Lee KS
The Kaohsiung journal of medical sciences. 2004 ; 20 (3) : 124-127.
PMID 15124896
Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice.
Ka SM, Sytwu HK, Chang DM, Hsieh SL, Tsai PY, Chen A
Journal of the American Society of Nephrology : JASN. 2007 ; 18 (9) : 2473-2485.
PMID 17687076
Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.
Kim S, Fotiadu A, Kotoula V
Clinical immunology (Orlando, Fla.). 2005 ; 115 (3) : 286-294.
PMID 15893696
Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells.
Kim S, McAuliffe WJ, Zaritskaya LS, Moore PA, Zhang L, Nardelli B
Infection and immunity. 2004 ; 72 (1) : 89-93.
PMID 14688085
Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.
Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY
American journal of clinical pathology. 2005 ; 124 (2) : 282-287.
PMID 16040301
Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes.
Maeda T, Hao C, Tron VA
Journal of cutaneous medicine and surgery. 2001 ; 5 (4) : 294-298.
PMID 11907838
DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.
Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, Rochlitz C
International journal of cancer. Journal international du cancer. 2002 ; 102 (3) : 254-257.
PMID 12397645
Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas.
Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M
Cancer letters. 2000 ; 160 (1) : 89-97.
PMID 11098089
Alterations of Fas and Fas-related molecules in patients with silicosis.
Otsuki T, Miura Y, Nishimura Y, Hyodoh F, Takata A, Kusaka M, Katsuyama H, Tomita M, Ueki A, Kishimoto T
Experimental biology and medicine (Maywood, N.J.). 2006 ; 231 (5) : 522-533.
PMID 16636300
Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.
Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, Hyodoh F, Ueki H, Kusaka M, Kita S, Ueki A
Clinical and experimental immunology. 2000 ; 119 (2) : 323-327.
PMID 10632670
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.
Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A
Nature. 1998 ; 396 (6712) : 699-703.
PMID 9872321
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.
Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M
Cancer research. 2001 ; 61 (6) : 2759-2765.
PMID 11289159
Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.
Shen HW, Gao SL, Wu YL, Peng SY
World journal of gastroenterology : WJG. 2005 ; 11 (38) : 5926-5930.
PMID 16273601
Tumor vaccine based on cell surface expression of DcR3/TR6.
Shi G, Mao J, Yu G, Zhang J, Wu J
Journal of immunology (Baltimore, Md. : 1950). 2005 ; 174 (8) : 4727-4735.
PMID 15814697
Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo.
Shi G, Wu Y, Zhang J, Wu J
Journal of immunology (Baltimore, Md. : 1950). 2003 ; 171 (7) : 3407-3414.
PMID 14500635
Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW
Gynecologic oncology. 2007 ; 106 (1) : 112-118.
PMID 17490732
Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice.
Sung HH, Juang JH, Lin YC, Kuo CH, Hung JT, Chen A, Chang DM, Chang SY, Hsieh SL, Sytwu HK
The Journal of experimental medicine. 2004 ; 199 (8) : 1143-1151.
PMID 15078896
The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2002 ; 5 (2) : 61-68.
PMID 12111580
Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice.
Tang CH, Hsu TL, Lin WW, Lai MZ, Yang RS, Hsieh SL, Fu WM
The Journal of biological chemistry. 2007 ; 282 (4) : 2346-2354.
PMID 17099218
Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.
Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, Kobayashi H, Koizumi M, Toyoda E, Ito D, Kami K, Mori T, Fujimoto K, Doi R, Imamura M
International journal of cancer. Journal international du cancer. 2003 ; 106 (1) : 17-25.
PMID 12794752
DcR3/TR6 modulates immune cell interactions.
Wan X, Shi G, Semenuk M, Zhang J, Wu J
Journal of cellular biochemistry. 2003 ; 89 (3) : 603-612.
PMID 12761893
A TNF family member LIGHT transduces costimulatory signals into human T cells.
Wan X, Zhang J, Luo H, Shi G, Kapnik E, Kim S, Kanakaraj P, Wu J
Journal of immunology (Baltimore, Md. : 1950). 2002 ; 169 (12) : 6813-6821.
PMID 12471113
Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.
Wortinger MA, Foley JW, Larocque P, Witcher DR, Lahn M, Jakubowski JA, Glasebrook A, Song HY
Immunology. 2003 ; 110 (2) : 225-233.
PMID 14511236
Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.
Wroblewski VJ, Witcher DR, Becker GW, Davis KA, Dou S, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE
Biochemical pharmacology. 2003 ; 65 (4) : 657-667.
PMID 12566095
Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication.
Wu SF, Liu TM, Lin YC, Sytwu HK, Juan HF, Chen ST, Shen KL, Hsi SC, Hsieh SL
Journal of leukocyte biology. 2004 ; 75 (2) : 293-306.
PMID 14634066
Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.
Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J
International journal of cancer. Journal international du cancer. 2003 ; 105 (5) : 724-732.
PMID 12740925
Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.
Wu YY, Chang YC, Hsu TL, Hsieh SL, Lai MZ
The Journal of biological chemistry. 2004 ; 279 (42) : 44211-44218.
PMID 15475369
Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression.
Yang CR, Hsieh SL, Ho FM, Lin WW
Journal of immunology (Baltimore, Md. : 1950). 2005 ; 174 (3) : 1647-1656.
PMID 15661928
Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW
Cell death and differentiation. 2004 ; 11 Suppl 1 : S97-107.
PMID 15002040
Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3).
You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, Hsieh SL
Blood. 2008 ; 111 (3) : 1480-1488.
PMID 18006694
A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS
The Journal of biological chemistry. 1999 ; 274 (20) : 13733-13736.
PMID 10318773
Modulation of T-cell responses to alloantigens by TR6/DcR3.
Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, Gregorio T, Feng P, Qi S, Chen H, Cho YH, Li Y, Moore PA, Wu J
The Journal of clinical investigation. 2001 ; 107 (11) : 1459-1468.
PMID 11390428


This paper should be referenced as such :
Wu, J ; Han, B
TNFRSF6B (tumor necrosis factor receptor superfamily, member 6b, decoy)
Atlas Genet Cytogenet Oncol Haematol. 2008;12(4):334-338.
Free journal version : [ pdf ]   [ DOI ]

External links


HGNC (Hugo)TNFRSF6B   11921
Entrez_Gene (NCBI)TNFRSF6B    TNF receptor superfamily member 6b
AliasesDCR3; DJ583P15.1.1; M68; M68E; 
GeneCards (Weizmann)TNFRSF6B
Ensembl hg19 (Hinxton)ENSG00000243509 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000243509 [Gene_View]  ENSG00000243509 [Sequence]  chr20:63696652-63698682 [Contig_View]  TNFRSF6B [Vega]
ICGC DataPortalENSG00000243509
Genatlas (Paris)TNFRSF6B
Genetics Home Reference (NIH)TNFRSF6B
Genomic and cartography
GoldenPath hg38 (UCSC)TNFRSF6B  -     chr20:63696652-63698682 +  20q13.33   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)TNFRSF6B  -     20q13.33   [Description]    (hg19-Feb_2009)
GoldenPathTNFRSF6B - 20q13.33 [CytoView hg19]  TNFRSF6B - 20q13.33 [CytoView hg38]
Genome Data Viewer NCBITNFRSF6B [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AF104419 AF134240 AF217794 AW204999 AY124378
RefSeq transcript (Entrez)NM_003823 NM_032945
Consensus coding sequences : CCDS (NCBI)TNFRSF6B
Gene Expression Viewer (FireBrowse)TNFRSF6B [ Firebrowse - Broad ]
GenevisibleExpression of TNFRSF6B in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)8771
GTEX Portal (Tissue expression)TNFRSF6B
Human Protein AtlasENSG00000243509-TNFRSF6B [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtO95407   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtO95407  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProO95407
Domaine pattern : Prosite (Expaxy)TNFR_NGFR_1 (PS00652)    TNFR_NGFR_2 (PS50050)   
Domains : Interpro (EBI)TNFR/NGFR_Cys_rich_reg    TNFRSF6B_N   
Domain families : Pfam (Sanger)TNFR_c6 (PF00020)   
Domain families : Pfam (NCBI)pfam00020   
Domain families : Smart (EMBL)TNFR (SM00208)  
Conserved Domain (NCBI)TNFRSF6B
PDB (RSDB)3K51    3MHD    3MI8    4J6G    4KGG    4KGQ    4MSV    5L36   
PDB Europe3K51    3MHD    3MI8    4J6G    4KGG    4KGQ    4MSV    5L36   
PDB (PDBSum)3K51    3MHD    3MI8    4J6G    4KGG    4KGQ    4MSV    5L36   
PDB (IMB)3K51    3MHD    3MI8    4J6G    4KGG    4KGQ    4MSV    5L36   
Structural Biology KnowledgeBase3K51    3MHD    3MI8    4J6G    4KGG    4KGQ    4MSV    5L36   
SCOP (Structural Classification of Proteins)3K51    3MHD    3MI8    4J6G    4KGG    4KGQ    4MSV    5L36   
CATH (Classification of proteins structures)3K51    3MHD    3MI8    4J6G    4KGG    4KGQ    4MSV    5L36   
AlphaFold pdb e-kbO95407   
Human Protein Atlas [tissue]ENSG00000243509-TNFRSF6B [tissue]
Protein Interaction databases
IntAct (EBI)O95407
Ontologies - Pathways
Ontology : AmiGOprotein binding  extracellular region  extracellular space  apoptotic process  tumor necrosis factor-mediated signaling pathway  signaling receptor activity  negative regulation of apoptotic process  
Ontology : EGO-EBIprotein binding  extracellular region  extracellular space  apoptotic process  tumor necrosis factor-mediated signaling pathway  signaling receptor activity  negative regulation of apoptotic process  
Pathways : KEGGCytokine-cytokine receptor interaction   
REACTOMEO95407 [protein]
REACTOME PathwaysR-HSA-5669034 [pathway]   
Atlas of Cancer Signalling NetworkTNFRSF6B
Wikipedia pathwaysTNFRSF6B
Orthology - Evolution
GeneTree (enSembl)ENSG00000243509
Phylogenetic Trees/Animal Genes : TreeFamTNFRSF6B
Homologs : HomoloGeneTNFRSF6B
Homology/Alignments : Family Browser (UCSC)TNFRSF6B
Gene fusions - Rearrangements
Fusion : QuiverTNFRSF6B
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerTNFRSF6B [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)TNFRSF6B
Exome Variant ServerTNFRSF6B
GNOMAD BrowserENSG00000243509
Varsome BrowserTNFRSF6B
Genomic Variants (DGV)TNFRSF6B [DGVbeta]
DECIPHERTNFRSF6B [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisTNFRSF6B 
Broad Tumor PortalTNFRSF6B
OASIS PortalTNFRSF6B [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICTNFRSF6B  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DTNFRSF6B
Mutations and Diseases : HGMDTNFRSF6B
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)TNFRSF6B
DoCM (Curated mutations)TNFRSF6B
CIViC (Clinical Interpretations of Variants in Cancer)TNFRSF6B
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry TNFRSF6B
NextProtO95407 [Medical]
Target ValidationTNFRSF6B
Huge Navigator TNFRSF6B [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDTNFRSF6B
Pharm GKB GenePA36614
Clinical trialTNFRSF6B
DataMed IndexTNFRSF6B
PubMed144 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:29:45 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us